News & Updates
Filter by Specialty:
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
The addition of relacorilant to nab-paclitaxel provides survival benefits in patients with platinum-resistant ovarian cancer (PROC) compared with weekly taxane, according to the results of the phase III ROSELLA study, presented at ESMO Gyn 2025.
Relacorilant plus nab-paclitaxel prolongs survival in platinum-resistant ovarian cancer
03 Sep 2025
Ileostomy reversal after rectal cancer surgery: Does timing matter?
In a systematic review and meta-analysis evaluating surgical outcomes in low rectal cancer patients who underwent early vs late ileostomy reversal, the former appears to be less beneficial than the latter in terms of surgical complications.
Ileostomy reversal after rectal cancer surgery: Does timing matter?
03 Sep 2025
Atezolizumab plus chemo, bevacizumab improves survival in R/M cervical cancer
The addition of atezolizumab to first-line chemotherapy plus bevacizumab delivers significant improvements in survival among patients with PD-L1+ or PD-L1‒ persistent, recurrent, or metastatic (R/M) cervical cancer, results of a post hoc analysis of the BEATcc study have shown.
